Citation, commencement and interpretation

1.-(1) These Regulations may be cited as the Social Security (Industrial Injuries) (Prescribed Diseases) Amendment Regulations 2017 and come into force on 30th March 2017.

(2) In these Regulations "the Principal Regulations" means the Social Security (Industrial Injuries) (Prescribed Diseases) Regulations 1985(3).

Amendment of regulation 4 of the Principal Regulations

2.  In regulation 4 of the Principal Regulations (presumption that a disease is due to the nature of employment)(4), in paragraph (2) after "C32," insert "C34,".

Amendment of Schedule 1 to the Principal Regulations

3.-(1) Part 1 of Schedule 1 to the Principal Regulations (list of prescribed diseases and the occupations for which they are prescribed)(5) is amended as follows.

(2) In column 1-

(a)for A1 substitute-

"A1 Leukaemia (other than chronic lymphocytic leukaemia) or primary cancer of the bone, bladder, breast, colon, liver, lung, ovary, stomach, testis or thyroid.";

(b)in B6 omit the words "(including farmer's lung)";

(c)after C33 insert-

"C34 Extrinsic allergic alveolitis.";

(d)in D9 omit the words "with obliteration of the costophrenic angle".

(3) In column 2-

(a)for A1 substitute-

"Exposure to ionising radiation where the dose is sufficient to double the risk of the occurrence of the condition.";

(b)in B6, after the words "heterologous proteins" insert "or any other biological substance that causes extrinsic allergic alveolitis" and at the end insert "; or (f) any other workplace";

(c)after C33 insert-

"Exposure to airborne isocyanates; or to any other chemical substance that causes extrinsic allergic alveolitis.".

EXPLANATORY NOTE

(This note is not part of the Regulations)

These Regulations make amendments to the Social Security (Industrial Injuries) (Prescribed Diseases) Regulations 1985 (S.I. 1985/967) ("the Principal Regulations").

Regulation 2 amends regulation 4(2) of the Principal Regulations to include new prescribed disease C34 (extrinsic allergic alveolitis).

Regulation 3 makes amendments to Schedule 1 to the Principal Regulations. It amends the prescriptions for prescribed diseases A1 (leukaemia (other than chronic lymphocytic leukaemia) or primary cancer of the bone, bladder, breast, colon, liver, lung, ovary, stomach, testis or thyroid), B6 (extrinsic allergic alveolitis) and D9 (unilateral or bilateral diffuse pleural thickening). It also inserts new prescribed disease C34.

A full impact assessment has not been published for this instrument as it has no impact on the private sector or civil society organisations.